Skip to main content
SpringerLink
Log in

Variability in the Diagnosis and Management of Patients with Alzheimer’s Disease and Cerebrovascular Disease

Results from the GALATEA Multicentre, Observational Study

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and objectives:

There is frequently a degree of variability among different types of dementia specialists in clinical practice in both the clinical diagnosis and the management of patients with Alzheimer’s disease and cerebrovascular disease (CVD). This variability may have an adverse effect on the use of medical resources as well as on patients’ well-being. The main objective of this study was to describe the current diagnosis and management of patients with Alzheimer’s disease and CVD in Spain. Other objectives were to determine whether there were significant differences in the diagnosis and management of these patients depending on physician characteristics and/or patient profile.

Methods:

This was an epidemiological, cross-sectional, multicentre study in which 107 physicians participated and recruited patients with Alzheimer’s disease and CVD. During a 1-month period, physicians collected data on diagnosis, treatment, follow-up, adverse events and other characteristics of these patients. This study was performed under naturalistic conditions, and no restrictions were imposed on the physicians.

Results:

Physicians were mainly neurologists (76%), geriatricians (14%) and psychiatrists (8%) with a median age of 42 years. A total of 720 patients with a diagnosis of Alzheimer’s disease and CVD were recruited. The median age of the patients was 78 years. Almost all patients were diagnosed by neuroimaging (98%) together with medical history (87%). The existence of a previous stroke coincident with cognitive deterioration was used as a diagnostic method in only 27% of patients. Among non-pharmacological treatment measures, diet was the most frequently recommended (61%), followed by cognitive stimulation (50%) and physical exercise (44%). The most commonly used pharmacological treatments were galantamine (59%), donepezil (14%) and rivastigmine (11%). The incidence of adverse events was low (3%), and all were considered non-severe. There were no significant correlations between physician age or physician years of practice and the diagnostic method used. The diagnostic method most frequently used by psychiatrists (100%) and geriatricians (97%) was medical history whereas this method was not used as much by neurologists (85%) [p = 0.0150]. Neuroimaging methods were more frequently used by neurologists (99%) and geriatricians (96%) compared with psychiatrists (84%) [p < 0.0001]. Patients with attention disorders had a higher frequency of follow-up visits (p = 0.0145) and were treated less frequently with donepezil (p = 0.0118).

Conclusions:

Several possible areas of improvement in the management of patients with Alzheimer’s disease and CVD were identified. These included better control of cardiovascular risk factors, such as hypertension and hyperlipidaemia, which have a high prevalence in this population, as has been shown in the present study. These potentially modifiable risk factors may assist in the prevention of Alzheimer’s disease. Also identified was the need to emphasize the role of general practitioners in decreasing the time to diagnosis of Alzheimer’s disease. Development of well designed clinical practice guidelines may help physicians decide on the most appropriate ways of diagnosing and managing patients with Alzheimer’s disease and CVD and reduce practice variations between different medical specialities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Klafki HW, Staufenbiel M, Kornhuber J, et al. Therapeutic approaches to Alzheimer’s disease. Brain 2006 Nov; 129 (Pt 11): 2840–55

    Article  PubMed  Google Scholar 

  2. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke 2004; 35 (11 Suppl. 1): 2620–2

    Article  PubMed  Google Scholar 

  3. Munoz DG, Feldman H. Causes of Alzheimer’s disease. CMAJ 2000; 162(1): 65–72

    PubMed  CAS  Google Scholar 

  4. Jellinger KA. Head injury and dementia. Curr Opin Neurol 2004; 17(6): 719–23

    Article  PubMed  Google Scholar 

  5. Tyas SL, Manfreda J, Strain LA, et al. Risk factors for Alzheimer’s disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol 2001; 30(3): 590–7

    Article  PubMed  CAS  Google Scholar 

  6. Kerr ML, Small DH. Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer’s disease: function, regulation of proteolysis, and implications for drug development. J Neurosci Res 2005; 80(2): 151–9

    Article  PubMed  CAS  Google Scholar 

  7. Wang B, Jin F, Yang Z, et al. The insertion polymorphism in angiotensin-converting enzyme gene associated with the APOE epsilon 4 allele increases the risk of late-onset Alzheimer disease. J Mol Neurosci 2006; 30(3): 267–71

    Article  PubMed  CAS  Google Scholar 

  8. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 2007; 6(4): 373–8

    Article  PubMed  CAS  Google Scholar 

  9. Cacabelos R, Fernandez-Novoa L, Lombardi V, et al. Cerebrovascular risk factors in Alzheimer’s disease: brain hemodynamics and pharmacogenomic implications. Neurol Res 2003; 25(6): 567–80

    Article  PubMed  CAS  Google Scholar 

  10. Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16(3): 131–6

    Article  PubMed  CAS  Google Scholar 

  11. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer’s disease, 2000–2050: potential implication of treatment advances. Ann Rev Public Health 2002; 23: 213–31

    Article  Google Scholar 

  12. Haan MN, Wallace R. Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health 2004; 25: 1–24

    Article  PubMed  Google Scholar 

  13. Dufouil C, Alperovitch A. Epidemiology of Alzheimer’s disease [in French]. Rev Prat 2005; 55(17): 1869–78

    PubMed  Google Scholar 

  14. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006; 14(7): 561–72

    Article  PubMed  Google Scholar 

  15. Olazaran J, Muniz R, Reisberg B, et al. Benefits of cognitivemotor intervention in MCI and mild to moderate Alzheimer disease. Neurology 2004; 63(12): 2348–53

    Article  PubMed  CAS  Google Scholar 

  16. Clare L, Woods RT, Moniz Cook ED, et al. Cognitive rehabilitation and cognitive training for early-stage Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev 2003; (4): CD003260

  17. Looi JC, Sachdev PS. Vascular dementia as a frontal subcortical system dysfunction. Psychol Med 2000 Sep; 30(5): 997–1003

    Article  PubMed  CAS  Google Scholar 

  18. Antoine V, Rigaud AS. Alzheimer’s disease: cardiovascular risk factors must be assessed [in French]. Rev Med Interne 2006; 27(1): 21–31

    Article  PubMed  CAS  Google Scholar 

  19. Cowppli-Bony P, Dartigues JF, Orgogozo JM. Vascular risk factors and Alzheimer disease risk: epidemiological studies review. Psychol Neuropsychiatr Vieil 2006; 4(1): 47–60

    PubMed  Google Scholar 

  20. Rockwood K. Mixed dementia: Alzheimer’s and cerebrovascular disease. Int Psychogeriatr 2003; 15Suppl. 1: 39–46

    Article  PubMed  Google Scholar 

  21. Fernando MS, Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol sci 2004; 226(1–2): 13–7

    Article  PubMed  Google Scholar 

  22. Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Methods Find Exp Clin Pharmacol 2007 Jul; 29Suppl. A: 1–91

    PubMed  CAS  Google Scholar 

  23. Kalaria RN. Comparison between Alzheimer’s disease and vascular dementia: implications for treatment. Neurol Res 2003; 25(6): 661–4

    Article  PubMed  Google Scholar 

  24. Davis P, Gribben B, Scott A, et al. The ’supply hypothesis’ and medical practice variation in primary care: testing economic and clinical models of inter-practitioner variation. Soc sci Med 2000; 50(3): 407–18

    Article  PubMed  CAS  Google Scholar 

  25. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98

    Article  PubMed  CAS  Google Scholar 

  26. Whitmer RA, Gunderson EP, Quesenberry Jr CP, et al. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 2007; 4(2): 103–9

    Article  PubMed  CAS  Google Scholar 

  27. Luchsinger JA, Reitz C, Honig LS, et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65(4): 545–51

    Article  PubMed  CAS  Google Scholar 

  28. Hayden KM, Zandi PP, Lyketsos CG, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 2006; 20(2): 93–100

    Article  PubMed  Google Scholar 

  29. Skoog I, Gustafson D. Update on hypertension and Alzheimer’s disease. Neurol Res 2006; 28(6): 605–11

    Article  PubMed  Google Scholar 

  30. Wilkinson D, Stave C, Keohane D, et al. The role of general practitioners in the diagnosis and treatment of Alzheimer’s disease: a multinational survey. J Int Med Res 2004; 32(2): 149–59

    PubMed  CAS  Google Scholar 

  31. Solomon PR, Murphy CA. Should we screen for Alzheimer’s disease? A review of the evidence for and against screening Alzheimer’s disease in primary care practice. Geriatrics 2005; 60(11): 26–31

    PubMed  Google Scholar 

  32. Thomas JM. Early screening of Alzheimer’s disease by the general practitioner: review of the literature. Rev Med Brux 2005; 26(4): S279–88

    PubMed  CAS  Google Scholar 

  33. Pope SK, Shue VM, Beck C. Will a healthy lifestyle help prevent Alzheimer’s disease? Annu Rev Public Health 2003; 24: 111–32

    Article  PubMed  Google Scholar 

  34. Polidori MC. Oxidative stress and risk factors for Alzheimer’s disease: clues to prevention and therapy. J Alzheimers Dis 2004; 6(2): 185–91

    PubMed  CAS  Google Scholar 

  35. Grytten J, Sorensen R. Practice variation and physician-specific effects. J Health Econ 2003; 22(3): 403–18

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the work of Virginia Mas in carrying out the statistical analysis of the study, HealthCo Spain for assistance with the preparation of the article, and Janssen-Cilag for funding support for the project. Dr Guzmán is an employee of Janssen-Cilag. The other authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Servicio de Geriatria, Hospital Clinico San Carlos, Madrid, Spain

    Pedro Gil

  2. Unidad de Neurologia, Fundaciön Hospital Alcorcón, C/Budapest S/N, Alcorcón, 28927, Madrid, Spain

    José Luis Dobato Ayuso

  3. Department of Neurology, Hospital Juan Canalejo, La Coruña, Spain

    José Manuel Marey

  4. Geriatric Unit, Cáceres Hospital Center, Cáceres, Spain

    Manuel Antón

  5. Medical Department, Janssen-Cilag, Madrid, Spain

    Carlos Guzmán Quilo

Authors
  1. Pedro Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Luis Dobato Ayuso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. José Manuel Marey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manuel Antón
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carlos Guzmán Quilo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José Luis Dobato Ayuso.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gil, P., Ayuso, J.L.D., Marey, J.M. et al. Variability in the Diagnosis and Management of Patients with Alzheimer’s Disease and Cerebrovascular Disease. Clin. Drug Investig. 28, 429–437 (2008). https://doi.org/10.2165/00044011-200828070-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200828070-00004

Keywords

Search

Navigation